Tafamidis Meglumine Capsule

What This Tafamidis Shortage Record Means

The FDA Drug Shortages database lists this record for Tafamidis Meglumine Capsule (brand: VYNDAQEL) from Pfizer Inc. with a current status of To Be Discontinued. The affected dosage form is Capsule, presented as Vyndaqel, Capsule, 20 mg soft gelatin capsules. Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Sep 29, 2025 and was last updated Sep 29, 2025. The FDA cites the following reason: Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025. No other current shortage records match this generic in the database, which can signal that either the disruption is contained to one manufacturer or other suppliers have not yet formally reported a shortfall.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.